5002-xaluritamig-vs-standard-care-a-phase-3-trial-for-arpi-taxane ...
5002-xaluritamig-vs-standard-care-a-phase-3-trial-for-arpi-taxane ...
10 months ago
urotoday.com
Patient Selection and Outcomes for Partial Cystectomy in Muscle-Invasive Bladder Cancer - Wei Shen Tan
Patient Selection and Outcomes for Partial Cystectomy in Muscle-Inva…
6 months ago
urotoday.com
Clinical Scenario and Patient Preference Guide Radium-223 Use in mCRPC - Daniel Heinrich
Clinical Scenario and Patient Preference Guide Radium-223 Us…
1 week ago
urotoday.com
Renal Toxicity Associated with PSMA Targeted Therapy "Presentation" - Ines Camille Azrour
Renal Toxicity Associated with PSMA Targeted Therapy "Present…
1 week ago
urotoday.com
Phase 1B Trial Combines Xaluritamig with Hormone Therapy for Metastatic Prostate Cancer - Nicholas Zorko
Phase 1B Trial Combines Xaluritamig with Hormone Therap…
5 months ago
urotoday.com
IBCG Recommendations for Intermediate-Risk NMIBC Definitions and Management - Roger Li
IBCG Recommendations for Intermediate-Risk NMIBC Definitio…
5 months ago
urotoday.com
TRIPLE-SWITCH Trial Tests Docetaxel Addition for mHSPC Patients with Suboptimal PSA Response - Alexandra Sokolova
TRIPLE-SWITCH Trial Tests Docetaxel Addition for mHSPC Pat…
7 months ago
urotoday.com
PARP Inhibitors in Prostate Cancer: A Decade of Development and the …
6 months ago
urotoday.com
Final Analysis of Phase 3 POTOMAC Study in High-Risk NMIBC - Maria …
5 months ago
urotoday.com
Gut Microbiome and Prostate Cancer: How Diet Impacts Diseas…
7 months ago
urotoday.com
ARTISAN Trial: Evaluating Lead-212 PSMA Therapy for Advanced Pros…
6 months ago
urotoday.com
EMBARK Analysis: Testosterone Recovery Post-ADT in High-Risk P…
11 months ago
urotoday.com
Examining Survival Rates in Prostate Cancer: Exploring the ST…
Jun 5, 2023
urotoday.com
Beyond Lutetium PSMA: Exploring Terbium-161 for Treatment-Resist…
Apr 22, 2025
urotoday.com
Phase III PSMAfore Trial: Final Survival and Safety Data in mCRP…
9 months ago
urotoday.com
Symmetry, Visibility, and Control: The Advantages of the BioProtect …
7 months ago
urotoday.com
HoLEP vs ThuLEP: Comparing Laser Enucleation Techniques in …
Aug 17, 2024
urotoday.com
Complete vs Partial TURBT for Muscle-Invasive Bladder Cancer T…
Apr 22, 2025
urotoday.com
Reading and Reporting a PSMA PET Scan for Staging Prostate Cancer …
Dec 20, 2021
urotoday.com
PROMISE Criteria: Enhanced Survival Prediction in Prostate Ca…
Jun 11, 2024
urotoday.com
Targeting NSD2 to Reverse Treatment Resistance in Advance…
6 months ago
urotoday.com
EZH2 Inhibition in Prostate Cancer: MEVPRO-1 Phase III Trial Update …
11 months ago
urotoday.com
Targeting EZH2 in Prostate Cancer: The Role of Mevrometostat in Prev…
Jun 18, 2024
urotoday.com
Advancements in Lutetium-PSMA Therapy for Prostate Cancer: Clini…
Oct 1, 2024
urotoday.com
Final Results of the SunRISe-4 Study in Muscle-Invasive Bladder …
7 months ago
urotoday.com
Targeting SPP1+ Macrophages and the Adenosine Pathway to Boost …
6 months ago
urotoday.com
Integrating Advanced Practice Providers into Urological Practice …
9 months ago
urotoday.com
Analysis of MRI Use in the Diagnostic Pathway for Bladder C…
7 months ago
urotoday.com
Treatment Options for BCG-Unresponsive Non-Muscle-Invasiv…
7 months ago
urotoday.com
Phase III CAPItello-281 Trial Results for mHSPC with PTEN Loss - Kari…
6 months ago
urotoday.com
See more videos
Static thumbnail place holder